De novo weekly and biweekly darbepoetin alfa dosing in pediatric patients with chronic kidney disease
Pediatric Nephrology Aug 22, 2017
Warady BA, et al. – This study assessed pediatric patients initiating erythropoiesis–stimulating agent (ESA) therapy, regarding the efficacy and safety of darbepoetin alfa. This study indicated safe administration of recommended regimen either QW or Q2W to ESA–naïve pediatric patients with chronic kidney disease (CKD)–related anemia to achieve hemoglobin (Hb) targets of 10.0Â12.0 g/dl.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
